Maedi-visna virus Vif protein uses motifs distinct from HIV-1 Vif to bind zinc and the cofactor required for A3 degradation.
E3 ubiquitin ligase
HIV
cyclophilin
lentivirus
metalloprotein
protein complex
protein–protein interaction
viral protein
zinc
Journal
The Journal of biological chemistry
ISSN: 1083-351X
Titre abrégé: J Biol Chem
Pays: United States
ID NLM: 2985121R
Informations de publication
Date de publication:
Historique:
received:
10
09
2020
revised:
23
10
2020
accepted:
09
11
2020
pubmed:
20
1
2021
medline:
15
9
2021
entrez:
19
1
2021
Statut:
ppublish
Résumé
The mammalian apolipoprotein B mRNA-editing enzyme catalytic polypeptide-like 3 (APOBEC3 or A3) family of cytidine deaminases restrict viral infections by mutating viral DNA and impeding reverse transcription. To overcome this antiviral activity, most lentiviruses express a viral accessory protein called the virion infectivity factor (Vif), which recruits A3 proteins to cullin-RING E3 ubiquitin ligases such as cullin-5 (Cul5) for ubiquitylation and subsequent proteasomal degradation. Although Vif proteins from primate lentiviruses such as HIV-1 utilize the transcription factor core-binding factor subunit beta as a noncanonical cofactor to stabilize the complex, the maedi-visna virus (MVV) Vif hijacks cyclophilin A (CypA) instead. Because core-binding factor subunit beta and CypA are both highly conserved among mammals, the requirement for two different cellular cofactors suggests that these two A3-targeting Vif proteins have different biochemical and structural properties. To investigate this topic, we used a combination of in vitro biochemical assays and in vivo A3 degradation assays to study motifs required for the MVV Vif to bind zinc ion, Cul5, and the cofactor CypA. Our results demonstrate that although some common motifs between the HIV-1 Vif and MVV Vif are involved in recruiting Cul5, different determinants in the MVV Vif are required for cofactor binding and stabilization of the E3 ligase complex, such as the zinc-binding motif and N- and C-terminal regions of the protein. Results from this study advance our understanding of the mechanism of MVV Vif recruitment of cellular factors and the evolution of lentiviral Vif proteins.
Identifiants
pubmed: 33465707
pii: S0021-9258(20)00031-9
doi: 10.1074/jbc.RA120.015828
pmc: PMC7949081
pii:
doi:
Substances chimiques
Cullin Proteins
0
vif Gene Products, Human Immunodeficiency Virus
0
Cyclophilin A
EC 5.2.1.-
Zinc
J41CSQ7QDS
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
100045Subventions
Organisme : NIAID NIH HHS
ID : R01 AI116313
Pays : United States
Organisme : NIAID NIH HHS
ID : R37 AI116313
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM008283
Pays : United States
Organisme : NIGMS NIH HHS
ID : T32 GM149438
Pays : United States
Informations de copyright
Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.
Déclaration de conflit d'intérêts
Conflict of interest The authors declare that they have no conflicts of interest with the contents of this article.
Références
Genes Dev. 2004 Dec 1;18(23):2867-72
pubmed: 15574593
Viruses. 2013 Jul 23;5(7):1867-84
pubmed: 23881276
Sci STKE. 2006 May 16;2006(335):pe21
pubmed: 16705129
Curr Biol. 2003 Nov 11;13(22):2009-13
pubmed: 14614829
J Virol. 2010 Aug;84(16):8193-201
pubmed: 20519393
J Virol. 2009 Jan;83(2):494-7
pubmed: 18987154
Front Microbiol. 2019 Mar 19;10:565
pubmed: 30941116
Expert Rev Mol Med. 2010 Jan 22;12:e4
pubmed: 20096141
Nature. 2011 Dec 21;481(7381):371-5
pubmed: 22190037
Drug Target Insights. 2007;2:9-18
pubmed: 21901058
Virology. 2006 Jun 5;349(2):290-9
pubmed: 16530799
Nature. 2011 Dec 21;481(7381):376-9
pubmed: 22190036
J Virol. 2010 Jul;84(14):7378-95
pubmed: 20463079
J Biol Chem. 2006 Jun 23;281(25):17259-17265
pubmed: 16636053
J Virol. 2014 Nov;88(21):12528-40
pubmed: 25142583
Nature. 2014 Jan 9;505(7482):229-33
pubmed: 24402281
Nat Med. 2003 Nov;9(11):1404-7
pubmed: 14528300
Anal Biochem. 2010 Feb 15;397(2):218-26
pubmed: 19854146
Nat Struct Mol Biol. 2019 Dec;26(12):1176-1183
pubmed: 31792451
Structure. 2014 May 6;22(5):668-84
pubmed: 24657093
Vet Pathol. 2017 May;54(3):353-354
pubmed: 28438114
Cell Rep. 2015 May 26;11(8):1236-50
pubmed: 25981045
J Virol. 2014 Mar;88(6):3309-19
pubmed: 24390320
Proc Natl Acad Sci U S A. 2005 Aug 9;102(32):11444-9
pubmed: 16076960
J Virol. 2018 Feb 26;92(6):
pubmed: 29263270
BMC Mol Biol. 2008 Nov 18;9:104
pubmed: 19017397
Nucleic Acids Res. 2019 Jul 2;47(W1):W636-W641
pubmed: 30976793
Viruses. 2013 Apr 23;5(4):1175-207
pubmed: 23611847
PLoS Pathog. 2014 Mar 20;10(3):e1003997
pubmed: 24651404
PLoS Pathog. 2016 Dec 1;12(12):e1005958
pubmed: 27907174
Nat Rev Immunol. 2009 Feb;9(2):106-15
pubmed: 19165227
Mol Cell. 2013 Feb 21;49(4):632-44
pubmed: 23333304
Microbiol Immunol. 2016 Jun;60(6):427-36
pubmed: 27193350
Trends Genet. 2012 Feb;28(2):89-100
pubmed: 22197521
Science. 2003 Nov 7;302(5647):1056-60
pubmed: 14564014
Biotechniques. 2000 Jun;28(6):1102, 1104
pubmed: 10868275
Proc Natl Acad Sci U S A. 2006 Dec 5;103(49):18475-80
pubmed: 17132731